MONTREAL, July 28 2017 – SoundBite Medical Solutions Inc. (SBMS), a Montreal-based cardiovascular medical technology company, is pleased to announce that Martin Brouillette, Co-Founder and Chief Technology Officer, has been named Chief Executive Officer.
Martin is the one of the inventors of Soundbite’s proprietary technology and has been instrumental in all aspects of the company’s development to date including the recent First-in-Human trial. Martin has also spearheaded pre-clinical developments, driven the widening of the company’s products portfolio and was a key player in Soundbite’s very successful $15M Seed Round financing.
Martin will lead SoundBite to maximize its potential in developing not only treatments for interventional vascular care but also in the much larger field of vessel preparation, leveraging his strong technical expertise and leadership.
He succeeds Steven Arless, also a Co-Founder, who has resigned for personal reasons. Steve will continue to contribute to the success of the company by assuming the role of Chairman of the Board of Directors of the Corporation. During his tenure as CEO, SoundBite has grown from a university spin-off to one of the most promising pre-commercialization medical device companies in North America. His energy and dedication resulted in the development of SoundBite’s proprietary shock wave technology from a laboratory platform to a clinically tested medical device in less than two years.
On behalf of SoundBite’s employees, we wish both Martin and Steve much success in their new roles and look forward to working with them to make SoundBite a resounding success in the medical device field, primed to improve quality of life in atherosclerotic patients by addressing significant unmet clinical needs in peripheral and coronary artery disease, growing cardiovascular conditions now affecting more than 25 million North Americans.